Xiao Dan Wang

JYAMS PET Research & Development Ltd. engages in the production and sales of radiopharmaceuticals. Its business includes technology development and technology transfer of positron tracer and molecular probe. The company was founded on March 7, 2006 and is headquartered in Nanjing, China.

Founded in 2021, Shanghai Lanacheng Biotechnology Co., Ltd. is a subsidiary of Yantai Dongcheng Biochemicals Co., Ltd. that provides technology solution services. The company is based in Shanghai, China.

XingImaging LLC is a full-service CRO company based in Madison, CT. XingImaging provides the capability for PET radiotracer production and PET acquisition, supporting multi-center trials in the US and China, which require PET for study eligibility, disease evaluation, and treatment efficacy. The PET production facilities in the XingImaging network are located at class-4 hospitals in China, and the company is currently expanding to other regions. XingImaging is committed to producing radiotracers to support clinical trials in Alzheimer's disease. The company was founded in 2018 by Gilles Tamagnan, Piu Chan, John Seibyl, and Kenneth Marek, with Gilles Tamagnan serving as the CEO since then. The company has established a network of radiopharmaceutical tracer production and imaging centers for PET acquisition and image analysis, utilizing the most advanced neuroimaging tracer compounds available to be used in AD clinical trials.

Aprinoia Therapeutics, Inc. operates as a global clinical-stage biopharmaceutical company. It develops imaging diagnostic tools, targeted therapy drugs, and other products. The company was founded in 2015 and is headquartered in Cambridge, MA.